Wave Life Sciences announces that its antisense drug WVE-120102 has lowered mutant huntingtin protein in cerebrospinal fluid, but investors seem disappointed. Rather confusing – what do we know for sure?
UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein using a ‘single-shot’ virus delivery system.
This fall sees exciting announcements from a number of companies focused on novel Huntingtin Lowering technologies, including Wave, PTC and Voyager
The LEGATO-HD trial of laquinimod did not slow progression of Huntington's disease. Here's the lowdown.
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
Can we test drugs to delay or prevent the onset of Huntington's disease? New research suggests it's possible
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
WAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein
A potential HD biomarker has been uncovered in a recent clinical study